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1. Introduction
1.1 Donor lymphocyte infusion (DLI)
DLI is a method of adoptive immunotherapy used after hematopoietic stem cell
transplantation (HSCT). In order to augment an anti-tumor immune response or to
ensure that donor stem cells remain to engraft after HSCT, lymphocytes from the
original stem cell donor are infused (Porter et al. 2006, Loren et al. 2006).
DLI constitutes an approach of adoptive immunotherapy and has been identified
as an important and efficient therapy for patients with chronic myelogenous
leukemia (CML) and acute myelogenous leukemia (AML) relapsing after allogeneic
hematopoetic stem cell transplantation (allo-HSCT) (Kolb et al. 1990). Several
studies have confirmed that DLI induces complete remissions in 70-80% of
patients with relapsed CML in chronic phase (Drobyski et al.1993, Porter et al.
1994, Kolb et al. 1995, Collins et al. 1997), the majority of which has proven to
restore full donor chimerism and produce long-term complete molecular genetic
remissions which other method, such as imatinib, does not provide a definite cure
for relapsed after allo-HSCT (Kolb et al. 1995, Guglielmi et al. 2002, Raiola et al.
2003, Weisser et al. 2006). At present, DLI has been recommended by the
European Bone Marrow Transplantation (EBMT) Society as a standard therapy for
patients with CML relapsing after HSCT.
Several retrospective studies have proven that the main function of DLI against
leukemia is based on the graft-versus-leukemia (GVL) (Loren et al. 2008).
Additionally, T cell depletion of the allograft increases the risk of relapse (most
markedly in patients with CML) of leukemia, suggesting that donor T cells are
important effectors of the GVL response (Horowitz et al. 1990). The acted target
for a GVL reaction may be leukemia-specific (Bocchia et al. 1996, Clark et al.
2001). This hypothesis is strongly supported by the fact that GVL can occur even
in the absence of clinical graft-versus-host disease.
Complications of DLI include acute and chronic GVHD as well as bone marrow
aplasia, resulting in immunosuppression and susceptibility to opportunistic
infections (Loren et al. 2008).
1.2 Graft-versus-host disease (GVHD)
The most significant and common complication after DLI is acute and chronic
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GVHD, which constitutes a result of the recognition of recipient allogenic antigens
by T cells from the donor and may develop in 40-60% of the patients (Kolb et al.
1995, Collins et al.1997, Raiola et al. 2003). GVHD contributes significantly to
morbidity and mortality even after treatment with fully matched donor lymphocytes.
In some cases, DLI-induced GVHD may be very severe: 20-35% of DLI recipients
can be anticipated to develop grade III-IV acute GVHD (Loren et al. 2008).
Furthermore, acute GVHD may lead to death in up to 10% of the patients (Porter
et al. 1997).
In most studies on DLI, GVHD correlated with the GVL response (Collins et al.
1997, Loren et al. 2008). Over 90% of complete responders developed an acute
or chronic GVHD. Of 23 patients who did not experience GVHD, only three
achieved a complete remission (Collins et al. 1997). As DLI is a highly effective
salvage strategy for relapsed CML after allo-HSCT, there is a fervent need for a
strategy to reduce GVHD when DLI are put into practice.
1.3 Wilms’ tumor gene 1 (WT1)
WT1 is a gene of dual function, which was first considered as a tumor suppressor
gene of Wilms’ tumor and was demonstrated to act as an oncogene later (Haber et
al. 1990, Yamagami et al. 1996, Nishida et al. 2006, Ariyaratana et al. 2007). It is
located on chromosome 11p13 and encodes Wilms’ tumor 1 protein, a zinc-finger
transcription factor that is very important for normal cellular development and cell
survival (Call et al. 1990, Mundlos et al. 1993). WT1 has been found to be a potent
transcriptional regulator. The targets genes of WT1 are important for cellular
growth and metabolism, including extracellular matrix components, growth factors
and other transcription factors.
Although it is limited to low levels in normal adult tissues, the expression of WT1
protein is up-regulated in a high proportion of patients with acute lymphoblastic
leukemia (ALL), AML, myelodysplastic syndrome (MDS), and CML and in several
solid tumors, including lung, breast, prostate, and ovarian cancer (Miwa et al. 1992,
Brieger et al. 1995, Oji et al. 1999). Therefore, more and more studies have
focused on WT1. It has become increasingly apparent that WT1 in peripheral
blood (PB) or bone marrow (BM) plays a dual role, not only as target for
immunotherapy, but also as biomarker of state, stage, response to treatment,
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prognosis, and relapse of the disease (Inoue et al. 1994, Sugiyama et al. 2001,
Miyoshi et al. 2002, Ogawa et al. 2003, Barragan et al. 2004, Chiusa et al. 2006,
Paschka et al. 2008, Rezvani et al. 2009, Weber et al. 2009)
As for immunotherapies targeting WT1, both WT1 peptide vaccination and
adoptive transfer of WT1 specific CD8+ T cells as a novel immunotherapy have
made great progress. Osada et al. reported on a WT1-encoding Ad vector which is
capable of inducing effective immunity against WT1-expressing malignancies
(Osada et al. 2009). A clinical vaccination trial with GM-CSF, WT1.126-134 peptide
and keyhole limpet hemocyanin (KLH) could provide immunological, molecular
and preliminary clinical evidence of potential clinical efficacy in AML patients
(Keilholz et al. 2009). A combined PR1 and WT1 vaccine showed a vaccine-driven
anti-leukemia effect. These results support further studies of combination
immunization strategies in leukemia patients (Rezvani et al. 2008).
Investigation on adoptive immunotherapy with WT1-specific CD8+ T cells also
indicated that WT1 has become an increasingly attractive target molecule for the
development of efficient immunotherapy whose possibility has been strongly
indicated by the feasibility and potential efficacy of cytotoxic T lymphocytes (CTLs)
against WT1-specific peptides (Oka et al. 2000, Ohminami et al. 2000). For clinical
applications, T cells of desired antigen specificity were isolated or engineered to
express receptors that target infected or transformed cells and were then
expanded in culture (Brentjens et al. 2003, Blattman et al. 2004, Morgan et al.
2006, Gattinoni et al. 2006). The generation of WT1-specific responses of healthy
donors (HDs) and the establishment of T cell clones specific for WT1 indicated the
potential clinical impact of ex vivo expanded donor-derived WT1-specific CD8+ T
cells for adoptive immunotherapy (Weber et al. 2009).
However, it is difficult to isolate WT1-specific CD8+ T cells from HDs as for the
expression of WT1 in healthy volunteers (HVs) is restricted to hematopoietic
progenitor cells where WT1 is expressed at a low level. The new technology for
the separation of WT1-specific CD8+ T cells may open new avenues for the WT1-
mediated adoptive immunotherapy.
1.4 Multimer technologies
Identification and purification of antigen-specific T cells without altering their
functional status is a highly desirable goal for adoptive immunotherapy. Several
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methods based on antigen specificity, such as secretion assay (affinity matrix)
(Manz et al. 1995), Enzyme-linked immunosorbent spot (ELISPOT) assay
(Miyahira et al. 1995), intracellular cytokine staining (Murali-Krishna et al.1998)
and major histocompatibility complex (MHC) multimer procedures (Altman et al.
1996, McMichael et al. 1998, Busch et al. 1998), have been developed to directly
identify antigen-specific T cells over the past years. Only multimer based selection/
separation might constitute the most straight forward methods for both the
isolation and purification of antigen-specific T cells (Knabel et al. 2002).
The basic principle of multimer technologies is to use the natural T cell receptor
(TCR) ligand, the MHC-peptide complex, as a staining probe (Altman et al. 1996).
Multimerization causes higher binding avidity of the reagent when compared to
monomeric MHC-epitope complexes to TCRs on the surface of T cells, thus
allowing epitope-specific binding to T cells. MHC multimer reagents could be used
for identification of T cells with high specificity and sensitivity.
The traditional MHC multimers such as tetra- and pentamer have been developed
to identify antigen-specific CD8+ T cells (Yao et al. 2008). Tetrameric complexes
have been shown to bind stably and specifically to appropriate MHC/peptide-
specific T cells (Altman et al. 1996) and to permit both the detection and isolation
of antigen-specific T cells present at low numbers in the PBMCs (Busch et al.
1998). However the functional activity of MHC multimer-labeled T cells is
hampered by the persistence of TCR-MHC interactions and subsequently induced
signaling events (Whelan et al. 1999, Daniels et al. 2000, Maile et al. 2001,
O'Herrin et al. 2001). The negative impact of surface-bound TCR-ligands on T
cells makes the application of traditional MHC multimer technologies in adoptive
immunotherapy difficult.
However, a new novel MHC multimer technology-designated streptamer
technique-has been developed to ‘reversibly’ identify and purify the antigen-
specific T cells (Knabel et al. 2002). This approach displays the specificity and
sensitivity of conventional MHC multimer staining and do not affect the functional
status of the T cells (Knabel et al. 2002). Therefore the streptamer technique
seems to be more advantageous for adoptive immunotherapies described above
(Figure 1) (Neudorfer et al. 2007).
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Figure 1. The streptamer techmology. A) Functional, non-induced antigen-specific T cells
are purified through a magnetic field and released by D-biotin from the streptamer complex. B)
A reversible antigen specific T cell is acquired by fluorescent labeled streptamer and D-biotin
induced removal of the complex.
1.5 Antigen-specific cytotoxic T cells
A cytotoxic T cell (also known as TC, CTL, T killer cell, cytolytic T cell, CD8+ T cell
or killer T cell) is a sub-group of T lymphocytes that are capable of recognizing and
inducing the death of infected somatic or tumor cells; they kill cells that are
infected with pathogens, such as viruses, bacterial and fungi, or are otherwise
damaged or dysfunctional.
Cytotoxic T cells could recognize antigen presented by MHC class I-derived
molecules which preserve peptides from protein degradation inside the cell and
present these peptides on the cell surface to CTL. This process enables CTL to
scan other cells for alterations (Andersen et al. 2006). The affinity between CD8
and the MHC molecule keeps the CTL and the target cell bound closely together
during antigen-specific activation. Cytotoxicity is exerted directly through the Fas
or perforin pathway and/or indirectly by the release of cytokines.
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The main function of the CTL is to monitor all the cells of the body, ready to
destroy any threat to the integrity of the host. Therefore, it is reasonable to suggest
that CTL could provide some degree of protection against spontaneous malignant
tumors. When the quantitative and qualitative antigenic differences in transformed
cells were detected, CTL has the ability to recognize and kill them.
WT1-specific cytotoxic T cells could specifically recognize and lyse the tumor cells
that express WT1 antigen. Therefore they can be used for the treatment of
patients with WT1 expressing tumors.
1.6 Rationale of the study
In order to maximize the anti-tumor effect and to minimize anti-host reactivity,
several approaches to DLI have been investigated, including: (1) Ex vivo activation
and expansion of donor T cells through co-stimulation; (2) generation and infusion
of tumor-specific T cells; (3) generation and infusion of minor histocompatibility
antigen-specific T cells; (4) low-dose DLI followed by dose escalation; (5) infusion
of selected T cell subsets (that is, after CD8+ cell depletion or CD4+ cell selection);
(6) inactivation of alloreactive T cells (that is, through transduction of suicide genes
into donor T cells, photochemical inactivation, inactivation by chemotherapy,
irradiation); (7) infusion of T regulatory cells; (8) generation and infusion of Th2-
type T cells; (9) manipulation of antigen presenting cells to maximize GVL or
minimize GVHD (Loren et al. 2008). Based on the data and considering the
cumulative international experience, the use of tumor antigen-specific DLI is
recommended to be a most attractive method of adoptive immunotherapy (Or et al.
2006) and suggested that such safer strategies above should focus on more
selective targeting of specifically immune T cells and recombinant interleukin-2-
activated natural killer cells (Falkenburg et al. 1993, Morecki et al. 2001, Slavin et
al. 2001, Slavin et al. 2003, Slavin et al. 2004) rather than using non-selective and
hazardous non-specific T cell therapy or antibody-guided recombinant interleukin-
2-activated lymphocytes (Morecki et al. 2006). So, the application of specific
effector cells that exert potent anti-tumor immunity with a lower risk of inducing
clinical GVHD might offer an ideal approach.
Wilms’ tumor protein (WT1), as an endogenous host protein, is over-expressed in
the chronic phase and particularly in the blast crisis of CML as well as in a more
than 70% of the patients with AML and MDS (Tamaki et al. 1999, Rosenfeld et al.
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2003). WT1 could serve as a potential myeloid leukemia tumor antigen. Therefore,
it was logical to start testing WT1-specific T cells generated and expanded in vitro
as tumor-specific DLI. Some studies have identified that the selection of WT1-
specific CD8+ T cells may be a promising method for the adoptive T cell
immunotherapy (Weber et al. 2009).
However, the problem is how to get qualified WT1-specific CD8+ T cells for
successful DLI. The advantage of streptamer technology above indicate that it may
be the most promising technology to choose for the development of adoptive T
cells transfer regimens for the treatment of patients with malignancy or infectious
diseases.
Here, we investigated whether WT1-specific CD8+ T cells separated by the
streptamer technique for DLI will increase the GVL. Studies investigating the
streptamer technology and the function of WT1-specific CD8+ T cell separated by
streptamer technology will indicate possible implications for adoptive
immunotherapy after allogeneic stem cell transplantation.
1.7 The aim of the study
T cell depletion without selection may effectively prevent severe GVHD but
profoundly impair donor-derived immune reconstitution and increase infection and
disease relapse. Generation and infusion of WT1-specific CD8+ T cells might be
an ideal option to enhance an anti-leukemic effect and to reduce GVHD after
hematopoeitic stem cell transplantation. In this study we evaluated the following
aspects of WT1-specific CD8+ T cells / of streptamer technology:
● Frequency of WT1-specific CD8+ T cells in healthy donors (HDs)
● Frequency of WT1-specific CD8+ T cells in AML patients
● Augmentation of the frequency of WT1-specific CD8+ T cells through MLPC
● Purification of WT1-specific CD8+ T cells by streptamer technology
● Immunophenotype of WT1-specific CD8+ T cells before and after column
separation
To answer these questions, the frequencies of WT1-specific CD8+ T cells in HDs
and patients were identified. Mixed lymphocyte peptide cultures of HLA-A*0201
positive/WT1 streptamer positive HDs and patients were performed. Antigen
specific T cells were isolated by using WT1 streptamer magnetic beads from
PBMCs of HDs. In order to investigate the immunophenotype of WT1-specific
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CD8+ T cells purified by streptamer, the samples of HDs before and after isolating
were identified by the staining of phenotypic markers.
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2. Material and Methods
2.1 Material
2.1.1 Samples
Blood samples were obtained from healthy donors at the Red Cross Blood Center,
Ulm, Germany after informed consent was obtained.
2.1.2 Reagents
Bovine Serum Albumin (BSA) Serva Electrophoresis GmbH,
Heidelberg
D-Biotin Stock Solution for
Streptamer Technology
IBA GmbH, Germany
Dimethyl sulfoxide (DMSO) Sigma-Aldrich, Steinheim, Germany
Ficoll-Biocoll Separation Solution Biochrom AG, Berlin, Germany
Human AB Albumin DRK Blutspendedienst, Mannheim,
Germany
Human AB Plasma DRK Blutspendedienst, Ulm,
Germany
Interleukin-7 (IL-7) Strathmann, Biotec GmbH
Interleukin-2 (IL-2) Sigma, Steinheim, Germany
β2-MG Sigma, Steinheim, Germany
L-Glutamine Biochrom AG
MHC IBA GmbH, Göttingen,Germany
Penicillin Invitrogen Gibco, Grand Island, USA
RPMI 1640 Biochrom AG, Berlin, Germany
Streptomycin Invitrogen Corporation, USA
Tween 20 Sigma
WT1-derived peptide (pos: 126-134 GL Biochem (shanghai) Ltd.
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RMF PNA PYL).
2.1.3 Antibodies
Alexa Fluor 647 Rat Anti-Human
CD197 (CCR7)
BD Biosciences, USA
APC Mouse Anti-Human CD69 BD Biosciences, USA
APC Mouse Anti-Human CD137 BD Biosciences, USA
PE Mouse Anti-Human CD19 BD Biosciences, USA
FITC Mouse Anti-Human CD4 BD Biosciences, USA
FITC Mouse Anti-Human CD8 BD Biosciences, USA
FITC Mouse Anti-Human CD28 BD Biosciences, USA
FITC Mouse Anti-Human CD45RA BD Biosciences, USA
FITC Mouse Anti-Human
CD107a
BD Biosciences, USA
FITC Mouse Anti-Human
HLA-A2
BD Biosciences Pharmigen
PerCP Mouse Anti-Human CD3 BD Biosciences, USA
PerCP Mouse Anti-Human CD8 BD Biosciences, USA
APC Rat IgG2a,κ Isotyp control BD Biosciences, USA
PE Mouse IgG1,κ Isotype Control BD Biosciences Pharmigen
FITC Mouse IgG1,κ Isotype Control
BD Biosciences Pharmigen
PerCP Mouse IgG1 Isotype Control BD Biosciences Pharmigen
CD8 magnetic-activated cell sorting
(MACS) beads, (CD8 microbeads,
human)
Miltenyi Biotec, Bergisch Gladbach,
Germany
Magnetic Beads for Streptamer
Technology
IBA GmbH
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Strep-Tactin PE for Streptamer
Technology
IBA GmbH
BD CalibriteTM Beads BD Biosciences, USA
HLA-A*0201 Tetramer WT-1 126-134
(RMFPNAPYL) PE
Ludwig Institute for Cancer Research,
Lausanne, Switzerland
HLA-A*0201 Tetramer Mutated
D227k/T228A WT-1 126-134
(RMFPNAPYL) PE
Ludwig Institute for Cancer Research,
Lausanne, Switzerland
2.1.4 Solutions and buffers
DPBS (10×) Invitrogen Coporation, USA
Destilled water Fresenius Kabi Deutschland GmbH, Homburg,
Germany
FACS Buffer PBS containing 1% BSA
BD FACS Flow BD Biosciences, Heidelberg, Germany
BD FACS Clean BD Biosciences
BD FACS Rinse BD Biosciences
Separation buffer
(PBS/EDTA buffer)
Miltenyi Biotec GmbH, Bergisch Gladbach, Germany
IS buffer IBA GmbH
2.1.5 Equipment
Autoclave WEBECO GmbH, Germany
24-well tissue culture plate
(flat bottom)
BD Biosciences, New Jersey, USA
-80 °C ultra low temperature freezer SANYO Electric Biomedical Co. Ltd,
Japan
96-well tissue culture plate
(flat bottom)
BD Biosciences, New Jersey, USA
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96-well tissue culture plate
(u-bottom)
BD Biosciences, New Jersey, USA
BD FACScanTM Flow Cytometer BD Biosciences, New Jersey, USA
Combitips plus (1.25 ml, 2.5 ml, 5
ml, 10 ml, 12.5 ml, 25 ml )
Eppendorf Ag, Hamburg, Germany
CS-15R Centrifuge Beckman Biotechnology, Germany
CS-6R Centrifuge Beckman Biotechnology, Germany
Ep T.I.P.S Reloads
0.1-20 μl, 2-200 μl, 50-1000 μl,
Eppendorf AG, Hamburg, Germany
Gloves VWR International GmbH,
Darmstadt, Germany
Hemocytometer chamber Optik Labor, Berlin, Germany
Inverse microscope Carl Zeiss, TELAVAC31, Germany
Light microscope Carl-Zeiss, Germany
Liquid nitrogen tank Model 8038 S/N 14830.59 Forma
Scientific Inc, Germany
Magnetic stirrer Ikamag TRC, Renner GmbH,
Ludwigshafen, Germany
MS columns Miltenyi Biotec, Bergisch Gladbach,
Germany
MACS Pre-Separation Filters Miltenyi Biotec, Bergisch Gladbach,
Germany
Non pyrogenic serologic pipettes
(2 ml, 5 ml, 10 ml, 25 ml, 50 ml)
Corning Incorporation, New York,
USA
Pipette Boy (IBS Pipetboy accu) Integra Biosciences AG, Chur,
Switzerland
Polypropylene Conical
Centrifuge Tubes (15 ml, 50 ml )
Becton and Dickinson Labware, NJ,
U.S.A
Power Pac TM HC Power Supply Bio-Rad, USA
Refrigerator Liebherr, Ochsenhausen, Gemany
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Sterile bench (Laminar flow cabinet ) TYP. HS 18/2, Heraeus instruments,
Germany
OctoMACSTM separator Miltenyi Biotec, Bergisch Gladbach,
Germany
Syringe (1 ml, 5 ml, 10 ml, 20 ml, 50
ml)
BD Biosciences, New Jersey, USA
Thermomixer Compact Thermon Eppendorf, Germany
Incubator Holder Heraeus, Hanau, Germany
Vortex-2TM genie Model G-560E, Scientific Industries,
Inc. Bohemia, NY, U.S.A
Waterbath GFL, Burgwedel, Germany
2.2 Methods
2.2.1 Ficoll density separation
All samples were taken from 40 HLA-A2+ healthy donors and 10 HLA-A2+ patients
after their informed consent was obtained in accordance with the Declaration of
Helsinki. Peripheral blood mononuclear cells (PBMCs) were isolated by Ficoll-
Biocoll Separation Solution density gradient centrifugation from
Ethylenediaminetetraacetic acid (EDTA) anticoagulated blood buffy coat
preparations from healthy donors or from EDTA anticoagulated blood samples
from patients. The viability of PBMCs obtained was always >95%, as determined
by trypan blue staining (Trypan Blue Solution 0.4%). The viable cells were
quantified in a Neubauer chamber. For cellular assays, Ficoll separated PBMCs
were tested freshly or cryopreserved in freezing medium (RPMI 1640 containing
20% human AB serum,100 units/ml penicillin, 100 units/ml streptomycin, 2 mM L-
glutamine and 10% DMSO) and stored in liquid nitrogen until further use. For
recovery, cryopreserved cells were thawed quickly and washed with plain medium
(RPMI 1640 containing 100 units/ml penicillin, 100 units/ml streptomycin, 2 mM L-
glutamine) for further use.
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2.2.2 Flow cytometry (FACS)
To evaluate the percentage of the WT1-specific CD8+ T cells, the samples were
analyzed by flow cytometry. CD8+ T cells were detected using a CD8-fluorescein
isothiocyanate (FITC) antibody and a CD3-peridinin chlorophyll (PerCP) antibody.
WT1-specific CD8+ T cells were measured by using the WT1 major histo-
compatibility complex with Strep-Tactin-Phycoerythrin (PE) conjugate. HLA-
A*0201/ WT1 peptide streptamer*PE was specifically synthesized at IBA GmbH.
Prior to staining, the WT1 major histocompatibility complex (MHC) was incubated
with PE-labeled Strep-Tactin for 45 min at 4oC in the dark. WT1/MHC was used at
a concentration of 0.1 µg, 0.2 µg, 0.4 µg, 0.6 µg and 0.8 µg to stain 1×106 cells in
100 µl per test. By this dilution chain, the appropriate amount of WT1/MHC-
streptamers to stain a pellet of 1×106 cells was defined as 20 µl (0.4 µg ) of the
WT1/MHC-streptamers (0.75 µg Strep-Tactin-PE with 2 µg MHC in a final volume
of 100 µl IS Buffer) and used for subsequent experiments.
For three-color staining, 10 μl anti-CD8*FITC and 10 μl anti-CD3*PerCP were
added at 4 oC for 20 minutes in the dark. After washing twice with 1×PBS, stained
cells were analyzed by flow cytometry (FACScan, CellQuest™). In all cases at
least 100,000 events were collected for analysis. Each sample was run with an
appropriate isotype control and this was used to define the stained cells. Analysis
was performed on tightly gated lymphocytes to exclude dead cells and debris.
2.2.3 Mixed lymphocyte peptide culture (MLPC)
CD8+ T lymphocytes were isolated from PBMCs by using CD8 magnetic-activated
cell sorting (MACS) beads. Briefly, cells were centrifuged at 1,200 rpm for 10
minutes with separation buffer (1 L PBS + 0.5% human Serum Albumin +1.9 mM
EDTA). Supernatants were removed carefully and cell pellets were resuspended in
80 μl of separation buffer and 20 μl of CD8 MicroBeads per 107 total cells. Cells
were mixed well and incubated for 15 minutes at 4oC. After incubation, 5 ml of
separation buffer were added to the tube and cells were centrifuged at 1,200 rpm
for 10 minutes. After centrifugation, cell pellets were resuspended in 500 μl of
separation buffer. MS column was placed in the magnetic field of OctoMACSTM
Separator and column was rinsed with 500 μl separation buffer once. Cell
suspensions above were applied onto the column. CD8- cells passed through the
column, while CD8+ cells were retained in the column. The column was washed
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with 500 μl separation buffer three times. Then column was removed from the
separator and placed on a 15 ml tube. 1 ml separation buffer was added to the
column and a plunger supplied with the column was firmly applied. CD8+ T
lymphocytes were collected in the tube.
After the PBMCs were isolated into CD8+ and CD8- fraction with a MACS column
according to the MACS protocol (Miltenyi, Bergisch-Gladbach, Germany), more
than 95% purity was reached in the CD8+ fraction as confirmed by flow cytometry.
Then, the CD8- antigen-presenting cells (APCs) were irradiated with 30 Gy and
pulsed with 20 µg/ml of the WT1-peptide (pos:126-134 RMF PNA PYL) and 2.5
µg/ml of the β2-Microglobulin (β2-MG) for 2 hours at 37°C, followed by a washing
step. After co-incubation of CD8- T lymphocytes with CD8+ T lymphocytes (2×106
CD8- cells : 5×105 CD8+ cells/ ml) over night at 37°C, 5% CO2 and 99% humidity,
the MLPC was supplemented with 10 U/ml recombinant human interleukin-2 (IL-2)
and 20 ng/ml IL-7 on day +1. On day +8 and day +14, the steps of incubation were
repeated. After 8, 14 and 21 days of culture, respectively, cells were harvested
and evaluated for the proliferation of WT1-specific CD8+ T cells by streptamer
staining and FACS analysis as described above.
The WT1 peptide used in our study was synthesized by Thermo Electron
Corporation to a minimum of 95% purity as measured by high performance liquid
chromatography. The peptide was dissolved in DMSO mixed with phosphate
buffered saline (PBS) at a concentration of 1 μg/μl for individual experiments.
2.2.4 Isolation of antigen-specific T cells using streptamer magnetic beads
First, the magnetic WT1/MHC-streptamer complex was used to label WT1-specific
CD8+ T cells according to their antigen specificity. Thereafter beads-labeled cells
were separated from non-specific cells by a magnetic field. Later, D-biotin was
added to the purified T cells. Briefly, this process was divided into three steps.
2.2.4.1 Preparation of WT1/MHC streptamer magnetic beads
After incubation of 50 µl streptamer magnetic beads, 8 µl WT1 MHC, and 90 µl IS
buffer over night at 4°C in the dark, 1 ml IS buffer was added to WT1/MHC-
streptamer magnetic bead solution and loaded on a MS column in the magnetic
field to wash away unbound MHC and streptamer magnetic beads. Then the MS
column was taken outside of the magnetic field and the retained beads were firmly
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flushed out by 250 µl IS Buffer using the supplied plunger supplied with the column.
2.2.4.2 Preparation of peripheral blood mononuclear cells (PBMC)
The procedure was optimized to isolate antigen-specific T cells from 2×107
peripheral blood mononuclear cells. Higher cell numbers require larger amounts of
MHC-streptamer magnetic beads. Cryopreserved PBMCs were thawed quickly
and washed with 20 ml plain medium (RPMI 1640 containing 100 units/ml
penicillin, 100 units/ml streptomycin, 2 mM L-glutamine). After washed with IS
buffer and resuspended in 10 ml IS buffer, these cells passed through enclosed
100 µm nylon mesh to remove cell clumps which may clog the columns. 2×107
cells were taken and placed on ice for further use.
2.2.4.3 Magnetic cell separation (MACSTM) by columns
2×107 cells were mixed with 250 µl WT1/MHC-streptamer magnetic bead solution
prepared above and incubated 45 minutes at 4°C in the dark. Then, these cells
were washed twice with IS buffer to eliminate unbound magnetic beads which may
trap cells on the column unspecifically and resuspended in 2 ml IS buffer for
magnetic separation.
The MS columns were placed into the magnetic field and prepared by rinsing with
3 ml IS buffer. Then the resuspended cells were applied onto the columns allowing
the cells to pass through and collect effluent. After the columns were washed three
times with 2 ml IS buffer, the columns were taken outside of the magnetic field and
were eluted with three times 2 ml IS buffer into a fresh vial. Thus, the positive cell
fraction was collected for further study.
2.2.4.4 Dissociation of streptamers by D-biotin
The fraction of positive cells was centrifuged and resuspended in 2 ml IS buffer
containing 2 mM D-biotin and incubated on ice for 20 minutes twice. Thereafter the
cells were washed with 5 ml IS buffer 4 times. Then these cells were stained with
PE-labeled streptamers and FACS analysis was performed as described above.
2.2.5 Cell surface immunophenotyping by flow cytometry
Samples were analyzed by flow cytometry before and after separation with the
WT1 streptamer technology. The WT1/MHC-streptamer fluorochrome complex
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was prepared as described above. Before staining, the cells were washed and
resuspended in IS buffer, and subsequently incubated with the conjugate of
WT1/MHC-streptamer*PE for 45 minutes at 4°C in the dark. Then, the cells were
incubated with anti-CD8*PerCP, anti-CCR7*APC, anti-CD45RA*FITC, anti-
CD107a*FITC, anti-CD69*APC, anti-CD137*APC, anti-CD28*FITC for 45 minutes
at 4°C in the dark. After washing twice with 1×PBS, the cells were subjected to
four-color flow cytometry (BD FACS Calibur System) and analyzed by using the
FACS Weasel SoftwareTM .
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3. Results
3.1 Optimization of the streptamer technology
In order to assure the isolation of fully functional, non-induced antigen-specific T
cells, all the reagents and cells had reached 4oC before starting the protocol, and
all steps were performed at 4oC. Background levels were determined by
comparison with HLA/A2-seronegative healthy donor samples. The lowest
background signals were below 0.05%. A titration of the WT1/MHC was performed
for the selection of a standard concentration of streptamer WT1/MHC. WT1/MHC
at a concentration of 0.1 µg, 0.2 µg, 0.4 µg, 0.6 µg and 0.8 µg, respectively, per
1×106 cells in 100 µl per tube was tested in triplet. By comparison, appropriate
amounts of streptamer were used to stain a pellet of 1×106 cells, 20 µl (0.4 µg ) of
the MHC (0.75 µg Strep-Tactin-PE with 2 µg MHC in a final volume of 100 µl IS
Buffer) was used as a standard amount for subsequent experiments (Figure 2).
Higher concentrations of streptamer resulted in the detection of similar or even
lower T cell frequencies, indicating saturation.
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Figure 2 Different amounts of streptamer were added to obtain curves for optimal
staining procedures. The data show that 20 µl (0.4 µg) per 100µl of the MHC molecules was
an ideal concentration for streptamer staining. Higher concentrations of streptamer resulted in
the detection of similar or even lower T cell frequencies, indicating saturation.
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3.2 Identification of WT1-specific CD8+ T cells in healthy volunteers and in
patients
In order to investigate whether WT1-specific CD8+ T cells exist in healthy donors
and patients with AML, forty samples from HLA/A2-seropositive healthy donors
and ten samples from HLA/A2-seropositive patients were analyzed using
fluorescence-activated cell sorting (FACS) staining with WT1/HLA-A*0201
Streptamers. Identification of ten HLA/A2-seronegative healthy donors, as controls,
was also done and no WT1-specific CD8+ T cells were founded. All 40 HLA/A2-
seropositive healthy donors and ten patients with AML, we were able to detect
WT1-specific CD8+ T cells. The frequency of WT1-specific CD8+ T cells specifically
recognizing the HLA-A2 restricted WT1 epitope ranged from 0.08% to 1.61%
(Figure 3). In 21 (52.5%) of 40 HLA/A2-seropositive healthy donors, the
frequencies of over 0.5% of naive WT1 specific CD8+ T cell when compared to all
CD8+ T cells were detected, among which the frequencies of 8 healthy donors
over 1.0% (Table 1). In five AML patients in complete remission, 0.68 to 3.65% of
WT1-specific T cells could be detected, while another five patients at time of
diagnose/relapse, the frequencies ranged from 0.13 to 0.90% (Table 2).
Figure 3. Frequency of WT1-specific CD8+ T cells in the peripheral blood of healthy
donors. Mononuclear cells of the peripheral blood were stained with monoclonal antibodies
against CD8+ and WT1 peptide specific streptamers as described in the Material and Method
section. Panel A shows a high, Panel B a low frequency of double-positive WT1-specific CD8+
T cells observed in two different healthy donors.
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Table 1The percentage of CD8+ T cells specific for WT1 when compared to
all CD8+ T cells in HLA-A2+ healthy volunteers
Volunteer WT-1 specific CD8+ T cells / CD8+ T cells (%)
1 0.49
2 1.61
3 0.72
4 1.01
5 0.51
6 0.11
7 1.24
8 0.92
9 1.12
10 0.72
11 0.15
12 0.63
13 0.48
14 0.60
15 0.30
16 0.82
17 0.31
18 0.11
19 0.31
20 0.96
21 0.72
22 0.23
23 1.53
24 0.41
25 0.99
26 1.16
27 0.96
28 0.41
29 0.78
30 0.47
31 0.46
32 0.83
33 0.27
34 1.28
35 0.35
36 0.08
37 0.40
38 1.27
39 0.45
40 0.27
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Table 2. The percentage of CD8+ T cells specific for WT1 when compared to
all CD8+ T cells in HLA-A2+ patients
Disease status at
the time of analysis
Number WT-1 specific CD8+ T cells / 
CD8+ T cells (%)
1 0.13
2 0.58
3 0.43
4 0.90
At time of
diagnose/relapse
5 0.22
6 1.89
7 1.68
8 3.65
9 1.78
In CR
10 0.68
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3.3 Mixed lymphocyte peptide culture of HLA-A*0201 seropositive/ WT1
streptamer positive healthy donors and patients
To document the induction of specific T cell responses in healthy donors and
patients with AML, we tested the WT1-derived peptide (pos: 126-134 RMF PNA
PYL). Flow cytometry for WT1-specific CD8+ T cells from the peripheral blood was
performed after MLPC.
We evaluated the proliferation of WT1-specific CD8+ T cells on days 1, 8, and 15
of MLPC by streptamer staining and FACS analysis. When CD8+ T lymphocytes of
HLA-A*0201 seropositive and WT1 streptamer positive healthy donors and
patients were subjected to two rounds of stimulation with irradiated autologous
CD8- APCs pulsed with WT1 peptide, WT1-specific CD8+ T cells were effectively
expanded (Figure 4). The data from healthy donors as well as patients showed a
ten-fold but not higher increase in the percentage of HLA-A2/WT1 streptamer
(PE)-positive CD8+ T lymphocytes.
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Figure 4. Augmentation in frequency of WT1-specific CD8+ T cells through mixed
lymphocyte peptide cultures (MLPCs) of mononuclear cells of the peripheral blood
(PBMCs) from healthy donors. CD8+ T lymphocytes were subjected to one or two rounds of
stimulation with irradiated autologous CD8- antigen-presenting cells plused with WT1 peptide
as described in the Material and Methods section. The dot plots show the percentage of HLA-
A2/WT1 streptamer (PE)-positive CD8+ T lymphocytes. A. The percentage of HLA-A2/WT1
streptamer (PE)-positive CD8+ T lymphocytes in healthy donor after the 1st and 2nd round of
stimulation. B. The percentage of HLA-A2/WT1 streptamer (PE)-positive CD8+ T lymphocytes
in a patient after one or two rounds of stimulation as described above. Both sets of data
demonstrate a ten-fold increase in the percentage of HLA-A2/WT1 streptamer (PE)-positive
CD8+ T lymphocytes.
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3.4 Isolation of antigen-specific T cells by WT1 streptamer magnetic beads
To evaluate the purity of the enriched antigen-specific T cells, positive fractions
were stained and analyzed by flow cytometry. Before separating of PBMCs, the
WT1-specific CD8+ T cells ranged from 0.08% to 1.61% of the total CD8+ T cells
population. After separation, a purity of 30-50 fold increase could be observed for
WT1-specific CD8+ T cells of the total CD8+ T cell population. The maximum purity
we could achieve by this method was 91% (Figure 5).
Figure 5. Isolation of WT1-specific CD8+ T cells via magnetic cell separation (MACS) of
PBMCs from a HLA-A2+ healthy donor. The dot plots show the percentage of HLA-A2/WT1
streptamer (PE)-positive CD8+ T lymphocytes before and after separation. For subpopulations
of CD8+ T cells, a 30-50 fold increase in the percentage of HLA-A2/WT1 streptamer (PE)-
positive CD8+ T lymphocytes could be observed after MACS separation.
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3.5 Immunophenotyping of WT1-streptamer-specific CD8+ T cells
In order to investigate the immunophenotype of WT1-specific CD8+ T cells purified
by streptamer, the samples of HDs before and after separation were identified by
the staining of phenotypic markers. WT1-specific CD8+ T cells before and after
separation were consistently CD8+WT1Streptamer+CD28-CD45RA+CD69-CD107a-
CCR7-CD137- effector T cells, but of varying intensity for CCR7, the WT1
streptamer specific CD8+ T cells after isolation expressed a high percentage of
CCR7 cells. These results indicated that most purified WT1 streptamer specific
CD8+ T cells have an effector T cell immunophenotype (Figure 6).
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Figure 6. Immunophenotyping of WT1 streptamer specific CD8+ T cells. WT1 streptamer
specific CD8+ T cells were further characterized by FACS analysis, demonstrating the
existence of CD8+WT1Streptamer+CD28-CD69-CD45RA+CCR7-CD107a-CD137- T cells in the
peripheral blood of healthy donors, thus indicating the effector T cell status of these cells.
Panel A (before separation) and Panel B (after separation) expressed a similar immunopheno-
type, suggesting functional, non-induced WT1-specific CD8+ T cells were purified by
streptamer technology.
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4. Discussion
4.1 Streptamer technology
A novel multimer technology designated streptamers has been developed to
identify and purify antigen-specific CD8+ T cells (Neudorfer et al. 2007, Yao et al.
2008). The function of antigen-specific CD8+ T cells could be preserved after
separation from PBMCs by streptamer technique (Neudorfer et al. 2007).
Therefore the streptamer technique may open new avenues toward an innovative
immunotherapeutic approach: the selection of antigen-specific CD8+ T cells at the
good manufacturing practice (GMP) level for adoptive T cell transfer.
The main principle of the streptamer technology is based on strep-tags and strep-
tactin. Strep-tags, which are short peptides, have a high binding selectivity for
strep-tactin, an engineered streptavidin (Voss et al. 1997). The binding affinity (Kd:
1×10-6 M) of strep-tag II to strep-tactin is up to 100 times higher than to
streptavidin (Voss et al. 1997). Strep-tags can be fused to recombinant protein,
which allows efficient one-step purification of such fusion proteins on immobilized
strep-tactin under physiological conditions, thus preserving their bioactivity. If MHC
multimers based on the interaction of strep-tag II with strep-tactin could be
generated for T cell staining, it should thus be possible to competitively disrupt
multimers in the presence of relatively low concentrations of D-biotin, as for the
molecule D-biotin, which binds with higher affinity to strep-tactin (Kd1×10-13 M),
effectively competes with strep-tag II for the binding site (Knabel et al. 2002).
Streptamers complexes consist of peptide loaded HLA-strep-tag III molecules and
strep-tactin polymers. Human leukocyte antigen (HLA)-strep-tag III is a fusion
protein between one HLA monomer and two strep-tag II sequences sequentially
arranged by a short linker (Schmidt et al. 1996, Junttila et al. 2005). Strep-tag II is
a comprising eight amino acid residues peptide (Trp-Ser-His-Pro-Gln-Phe-Glu-Lys)
showing a strong binding affinity for an engineered streptavidin derivative called
strep-tactin (Voss et al. 1997). The binding affinity of strep-tag III to strep-tactin is
higher than strep-tag II to strep-tactin (Kd: 1×10-7 M) (Neudorfer et al. 2007).
Figure 1 showed the rationale about how a functional, non-induced antigen
specific T cell preparation was yielded by streptamer technology, indicating an
advance with regard to the isolation of antigen specific T cells when compared to
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conventional multimers technology (Knabel et al. 2002, Neudorfer et al. 2007).
The significant characteristic of the streptamer technology is the fact that it allows
the isolation of antigen-specific CD8+ T cells with preserved function and that is
available at GMP level (Neudorfer et al. 2007), whereas lytic function and
proliferation of the T cells is impaired in the presence of conventional MHC
multimers such as tetramer. Other important advantages of streptamer technology
have been identified, including the absence of toxicity to T cells, the lack of
adverse side effects for clinical in vivo application, the absence of immune
responses directed against the multimer reagents and the maintenance of the
capacity of the transferred T cells to migrate in vivo to localizations, where they are
required for immune reactions (Knabel et al. 2002, Neudorfer et al. 2007).
Therefore, the streptamer technique will be of great diagnostic and clinical value
and might facilitate the development of adoptive T cells transfer regimens for the
treatment of patients with cancer or infectious diseases (Neudorfer et al. 2007).
HLA-A2/CMV streptamers and HLA-A2/melan-A streptamers were used for the
identification and purification of antigen-specific CD8+ T cells. The results showed
that the quality of separation in terms of the number and the purity of isolated
CD8+ T cells was equally high for streptamer and tetramer. The reversibility of
streptamer resulted in preserved cytolytic activity of antigen-specific T cells after
identification. In contrast, tetramer-treated T cells displayed a reduced cytolytic
potential (Neudorfer et al. 2007). According to the manufacturer, the maximum
purity of CMV antigen-specific T cells they could achieve by streptamer technology
was 82%.
HLA-A2/WT1 streptamer has been developed to identify WT1-specific CD8+ T
cells, while little is known about the difference between the functional status of
WT1-specific CD8+ T cells mediated by streptamers and tetramers. We wondered
whether HLA-A2/WT1 streptamer had an advantage over HLA-A2 /WT1 tetramer
on the purification of CD8+ T cells which may facilitate the adoptive immunotherapy
of patients with malignancy tumor.
4.2 Detection of WT1 specific CD8+ T cells present at low numbers in the
PBMCs of healthy donors and patients
Both CMVpp65-specific/tetramers and the CMVpp65-specific /streptamer have been
used for the detection and isolation of CMV-specific CD8+ T cells present at low
Xinchao WANG Streptamer isolated WT1-specific T cells 29
number in the PBMCs (Busch et al. 1998, Keenan et al. 2001, Neudorfer et al.
2007, Yao et al. 2008), while WT1-specific/tetramers only have been used for the
measurement of WT1 specific CD8+ T cells immune response to the vaccine or
immunotherapy (Morita et al. 2006, Rezvani et al. 2007), as the percentage of
WT1-specific CD8+ T cells in the PBMCs of healthy donors is too low to be
detected by WT1/tetramer. Therefore we hoped to find a new technology to detect
WT1-specific CD8+ T cells present at low numbers in the PBMCs of healthy donors
and patients.
Only when the streptamer technology was used at 4oC in the dark, T cells could be
identified and purified without altering their original phenotype and functional
status (Knabel et al. 2002). Based on these data, we performed all the steps,
including the staining of the cells and the following dissociation, at 4oC in the dark.
In order to optimize the streptamer technology, a titration of the MHC/WT1 was
performed for the selection of a standard concentration of streptamer MHC/WT1
according to the amounts recommended by manufacturer. 20 µl (0.4 µg) of the
WT1/MHC (0.75 µg Strep-Tactin-PE with 2 µg MHC in a final volume of 100 µl IS
Buffer) was selected as a standard amounts to stain a pellet of 1×106 cells for
subsequent experiments (Figure 2). The results show that higher concentrations of
streptamer reagent resulted in the detection of similar or even lower T cell
frequency, an explanation for this observation might be a saturation phenomenon.
We evaluated the frequency of the WT1-specific CD8+ T cells in healthy donors by
the streptamer technology. All samples were analyzed using FACS staining with
WT1/HLA-A*0201 streptamers. Ten HLA/A2 negative healthy donors were used as
negative controls: no WT1-specific CD8+ T cells were found. In all 40 HLA/A2
positive healthy donors, we were able to detect WT1-specific CD8+ T cells. The
frequency of CD8+ T cells specifically recognizing the HLA-A2 restricted WT1
epitope ranged from 0.08% to 1.61% (Figure 3). In 21 (52.5%) of 40 HLA/A2
positive healthy donors, naive WT1-specific CD8+ T cell frequencies of more than
0.5% out of all CD8+ T cells were detected. In 8 healthy donors we detected
frequencies over 1.0% (Table 1). The frequency of the WT1-specific CD8+ T cells
in 10 patients with AML was also investigated, in five AML patients in complete
remission, also 0.68 to 3.65% of WT1-specific CD8+ T cells could be detected. In
contrast in another five patients at the time of diagnose/relapse, the frequencies
ranged only from 0.13 to 0.90% (Table 2). These results indicated that we were
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able to employ the streptamer technology to identify the WT1-specific CD8+ T cells
present at low numbers in the PBMCs of healthy donors and patients.
By streptamer technology, WT1-specific CD8+ T cells could be detected in all HLA-
A2 positive healthy donors, whereas WT1-specific CD8+ T cells were not detected
by tetramer staining in healthy donors (Rezvani et al. 2007). An explanation for the
difference in the amount of WT1-specific CD8+ T cells measured with different
multimers might be same as the CMV-specific CD8+ T cells: the incubation of
CMV-specific CD8+ T cells with CMV streptamers demonstrated high intensity T
cell staining that was comparable to conventional CMV tetramers (Neudorfer et al.
2007). The other reason for higher frequency of WT1-specific CD8+ T cells
measured by streptamer technology is the difference of the gate: CD8+ T cells, not
the lymphocyte cells, were used for the gate to analyze specific cells in our study.
The results showed that the streptamer technology could be used for the
identification of the WT1-specific CD8+ T cells present at low numbers in the
PBMCs of healthy donors.
Additionally, we found that among five AML patients in complete remission, also
0.68 to 3.65% of WT1-specific CD8+ T cells were detectable, while another five
patients at the time of diagnose/relapse, the frequencies ranged from 0.13 to
0.90%, suggesting a WT1-driven GVL effect to the former in CR, for the
emergence of WT1-specific CD8+ T cells was associated with a decrease in WT1
expression (Rezvani et al. 2007).
4.3 Purification of WT1-specific CD8+ T cells by streptamers
In our study, we found that streptamer technology showed a higher separation
quality in term of the purity of isolated WT1-specific CD8+ T cells. The data
showed a ten-fold but not higher increase in the percentage of HLA-A2/WT1
streptamer (PE)-positive CD8+ T lymphocytes in PBMCs of HLA-A*0201
seropositive healthy donors were acquired by MLPC, whereas a purity of
30- to 50-fold increase could be achieved through isolation by streptamer
technology for WT1-specific CD8+ T cells of the total CD8+ T cell population.
The results indicated that the streptamer technology is a promising method for
the purification/positive selection of WT1-specific CD8+ T cells.
Neudorfer et al. reported that the streptamer technology is not only as sensitive as
conventional tetramer technology regarding the detection and purification of
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minute cell amounts, but also allow the isolation of antigen-specific T cells with
preserved function (Neudorfer et al. 2007). To further investigate the functional
status of isolated T cells, the samples of healthy donors before and after
separation were identified by the staining of phenotypic markers.
CD8+ T cells can be dissected into four groups according to the state of
activation/differentiation. On the basis of CD45RA and CCR7 expression, the four
different subsets of CD8+ T lymphocytes were previously defined: naive (N:
RA+CCR7+), effector (E: RA+CCR7-), central-memory (CM: RA-CCR7+), and
effector-memory (EM: RA-CCR7-) T cells (Sallusto et al. 1999). Different states of
CD8+ T cells activation are associated with different functional and
immunophenotypic characteristics. WT1-specific CD8+ T cells identified by
streptamer technology were analyzed for expression of CD28, CD45RA, CD69,
CD107a, CCR7, and CD137 to characterize a naïve, memory, or effector
phenotype respectively. In our study, we found that WT1-specific CD8+ T cells
before and after isolation were consistently CD8+WT1streptamer+CD28-
CD45RA+CD69- CD107a-CCR7-CD137- effector T cells, but of little varying
intensity for CCR7, the WT1-streptamer-specific CD8+ T cells after isolation
expressed a higher percentage of CCR7+ cells. A frequency of almost 80% for
CCR7-/CD45RA+ cells was acquired. These results indicated that the naïve
functional status of CD8+ T cells purified by streptamer technology was preserved
and most isolated WT1 streptamer specific CD8+ T cells had an effector T cell
immunophenotype. Therefore WT1-specific CD8+ T cells isolated by streptamer
could confer immediate immune protection into peripheral tissues.
4.4 Streptamer technology as a promising way for DLIs
CML patients might experience a relapse after allogeneic peripheral blood stem
cell transplantation (allo-PBSCT). In general, there are two treatment options: DLI
or therapy with a tyrosine kinase inhibitor, such as imatinib, nilotinib or dasatinib.
DLI has been identified as an efficacious therapy for patients with CML and AML at
relapse after allo-HSCT. It could restore full donor chimerism and produce long-
term complete molecular genetic remissions and thus eventually providing cure for
the disease (Kolb et al. 1995, Guglielmi et al. 2002, Raiola et al. 2003, Weisser et
al. 2006). The effect of DLI against leukemia is mainly based on the GVL reaction.
However, a severe complication of DLI might be the development of acute and
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chronic GVHD, which results from the attack of the recipient’s organs by T cells
from the donor. GVHD may occur in 20%-60% of patients after allo-HSCT (Kolb et
al. 1995, Collins et al. 1997, Raiola et al. 2003), leading to significant morbidity
and mortality even after treatment with fully matched donor lymphocytes.
Therefore, a development of “safer” DLI with less aggressive and more selective
anti-cancer effects is urgently required. Selective targeting of specific immune T
cells, recombinant interleukin-2-activated natural killer cells and antibody-guided
recombinant interleukin-2-activated lymphocytes had been reported (Ruggeri et al.
1999, Slavin et al. 2001, Morecki et al. 2006). These reports above showed that a
selective anti-tumor reactivity of donor lymphocytes, which could be able to induce
a strong GVL effect with low grade GVHD or even no GVHD, might be a more
promising way for DLI.
In this study, we focused on the immunogenic leukemia-antigen (WT1). WT1 has
emerged as an important factor in normal and malignant hematopoiesis. The WT1
protein expression is up-regulated in a high proportion of patients with ALL, AML,
MDS, and CML and in several solid tumors, including lung, breast, prostate, and
ovarian cancer (Miwa et al. 1992, Brieger et al. 1995, Oji et al. 1999). Therefore, it
has become an increasingly attractive target molecule for the development of
efficient immunotherapy, the feasibility and potential efficacy of CTL against WT1-
specific peptides has been identified (Oka et al. 2000, Ohminami et al. 2000,
Weber et al. 2009).
Streptamer technology was selected to identify and purify WT1-specific CD8+ T
cells, as the streptamer reagent could be detached from the isolated WT1-specific
CD8+ T cells prior to transfer. Several side effects caused by reagents could be
avoided, including toxicity to T cells, harm for clinical in vivo application, immune
responses directed against the reagents and loss of the capacity of the transferred
T cells to migrate in vivo to localizations. Therefore, a functional, non-induced,
streptamer-selected antigen-specific CD8+ T cell, which could be available at GMP,
will facilitate the development of DLI (Neudorfer et al. 2007, Yao et al. 2008). In our
study, WT1-specific CD8+ T cells purified by streptamer technology showed an
effector T cell immunophenotype and cytotoxic potential, indicating a promising
method for adoptive immunotherapy.
In summary, streptamer technology which could be available at GMP level not only
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keeps promise to improve the specificity and sensitivity when compared to
tetramers, it also allows to purify antigen-specific T cells while preserving their
function. Therefore, streptamer technology constitutes a novel method for the
development of DLI.
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5. Summary
1) Background: Donor lymphocyte infusion (DLI) may generate a desirable graft-
versus-leukemia (GVL) effect, but also elicit a noxious graft-versus-host disease
(GVHD). A positive selection of leukemia (antigen)-specific T cells would be highly
desirable. In this study, we focused on the immunogenic leukemia-antigen Wilms’
Tumor gene 1 (WT1).
2) Aim: Here we investigated whether streptamer technology allows the
identification and isolation of WT1-specific CD8+ T cells without altering functional
status, thus facilitating the further development of DLI.
3) Material and methods: Peripheral blood samples from forty HLA/A2-
seropositive healthy donors (HDs) were characterized fluorescence-associated
cell separation by flow cytometry using WT1/HLA-A*0201 streptamers. We also
detected the frequency of WT1-specific CD8+ T cells in ten patients with AML. The
purification effect of WT1-specific CD8+ T cells from the healthy donors was
compared between streptamer technology and mixed lymphocyte peptide culture.
Furthermore, the samples of HDs before and after separation were identified by
the staining of phenotypic markers to investigate the immunophenotype of WT1-
specific CD8+ T cells isolated by streptamer technology.
4) Results: The frequency of CD8+ T cells specifically recognizing the HLA-A2
restricted WT1 epitope ranged from 0.08% to 1.61%. In 21 (52.5%) of 40 HLA/A2-
seropositive HDs, naive WT1-specific CD8+ T cell frequencies of more than 0.5%
of all CD8+ T cells were detected, in 8 HDs even frequencies higher than 1.0%. As
for the frequency of WT1-specific CD8+ T cells in patients with AML, 0.68 to 3.65%
of WT1-specific CD8+ T cells could be detected in five AML patients in complete
remission, while in five patients at the time of diagnose/relapse, the frequencies
ranged only from 0.13 to 0.90%. A ten-fold but not higher increase in the
percentage of HLA-A2/WT1 streptamer(PE)-positive CD8+ T lymphocytes in
PBMCs of HLA-A*0201 positive HDs was achieved by MLPC, whereas a purity of
30- to 50-fold increase could be obtained through purification by streptamer
technology for WT1-specific CD8+ T cells out of the total CD8+ T cell population.
WT1-specific CD8+ T cells before and after the separation were consistently
CD8+WT1streptamer+CD28-CD45RA+CD69-CD107a-CCR7-CD137- effector T cells,
a frequencies of almost 80% for CCR7-/CD45RA+ cells was acquired.
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5) Conclusion: Streptamer technology permits the detection of WT1-specific
CD8+ T cells present at low numbers in the PBMCs from both HDs and patients.
The streptamer technology is a promising method for the selection of WT1-specific
CD8+ T cells. The naïve functional status of CD8+ T cells separated by streptamer
technology was preserved and most isolated WT1-specific CD8+ T cells
demonstrated an effector T cell immunophenotype. Taken together, our study
indicated that streptamer technology available at GMP level opens new avenues
for the further development of DLIs.
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6. Zusammenfassung
1Hintergrund der Studie: Infusionen von Spender-Lymphozyten generieren
beim Empfänger einen erwünschten „Transplantat-gegen-Leukämie-Effekt“ (graft
versus leukemia; GVL), verursachen aber gleichzeitig eine schädliche
„Transplantat-gegen-Wirt-Krankheit“ (graft versus host disease; GVHD). Eine
positive Selektion von T-Lymphozyten, die spezifisch gegen ein Leukämie-Antigen
gerichtet sind, ist hierbei sehr wünschenswert. In dieser Arbeit haben wir uns auf
das Leukämie-Antigen Wilms-Tumor-Gen 1 (WT1) fokusiert.
2Ziel der Studie: Wir untersuchten hierbei, ob die Streptamer-Technologie die
Isolation von WT1-spezifischen CD8+ T-Zellen erlaubt, ohne dabei den
funktionellen Status und die Entwicklung der Spender-Lymphozyten zu verändern.
3Materialen und Methoden: 40 Proben von HLA/A2-seropositiven gesunden
Spendern wurden mit WT1/HLA-A*0201-Streptamer Fluoreszenz-markiert und
durchflusszytometrisch untersucht. Es wurden außerdem die Frequenzen von
WT1-spezifischen CD8+ T-Zellen in 10 Patienten mit AML untersucht. Wir
verglichen die Reinheit von WT1-spezifischen CD8+ T-Zellen von gesunden
Spendern nach der Isolation mit der Streptamer-Technik und der
Lymphozyten/Peptid-Kultur. Des Weiteren wurden die Proben von gesunden
Spendern vor und nach Separation durch Färbung mit phänotypischen Markern
untersucht, um den Immunphänotyp von WT1-spezifischen CD8+ T-Zellen
darzustellen.
4Ergebnisse: Die Häufigkeit von CD8+ T-Zellen, die speziell das HLA-A2 WT1-
Epitop erkennen, schwankte zwischen 0,08% und 1,61%. In 21 (52,5%) von 40
HLA-A2-seropositiven gesunden Spendern wurden WT1-spezifische T-Zellen mit
einer Frequenz von 0,5% detektiert. Bei acht gesunden Spendern lag die
Frequenz bei über 1,0%.
Bei fünf Patienten mit einer AML in Kompletter Remission fanden wir 0,68% bis
3,65% WT1-spezifische CD8+ T-Zellen, während die Häufigkeit bei weiteren 5
Patienten, die ein Rezidiv der AML aufwiesen, die Häufigkeit nur bei 0,13% bis
0,90% lag. Eine Steigerung der Ausbeute um das Zehnfache an HLA-A2/WT1-
Streptamer (PE)-positiven CD8+ T-Lymphozyten des peripheren Blutes von HLA-
A*0201-positiven gesunden Spendern wurde mittels Lymphozyten/Peptid-Kultur
erreicht. Eine Verbesserung der Reinheit von WT1-spezifischen CD8+ T-Zellen um
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das 30 bis 50fache konnte erreicht werden, indem man die Streptamer Technik auf
die CD8+ T-Zell-Population anwendete. WT1-spezifische CD8+ T-Zellen waren vor
sowie nach der Separation kongruent CD8+WT1streptamer+CD28-CD45RA+CD69-
CD107a-CCR7-CD137- T-Effektor-Zellen. Beinahe 80% CCR7-/CD45RA+ T-Zellen
wurden separiert.
5Schlussfolgerung: Die Streptamer-Technologie erlaubt die Erkennung auch
einer geringen Anzahl von WT1-spezifischen CD8+ T-Zellen im peripheren Blut von
gesunden Spendern und Patienten. Sie ist eine zuverlässige Methode für die
Isolierung von CD8+ T-Zellen mit hoher Reinheit. Die Funktionalität von CD8+ T
Zellen, die mittels Streptamer-Technik isoliert werden, bleibt erhalten. Die meisten
der Streptamer-spezifischen CD8+ T-Zellen sind T-Effektorzellen. Die untersuchte
Streptamer-Technik, die auf GMP-Level verfügbar ist, könnte für die weitere
Entwicklung von Spenderlymphozyten verwendet werden.
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